Neurodegenerative diseases characterized by the presence of α-synuclein-a hallmark of pathologic inclusions termed Lewy bodies-include Parkinson's disease, dementia with Lewy bodies, and multiple-system atrophy. Although motor symptoms are related to the altered presynaptic dopaminergic function in these diseases, the appearance of α-synuclein inclusions precedes the involvement of the nigrostriatal dopaminergic pathway. Hence, the most accurate and earliest definition of premotor Parkinson's disease ought to rely on imaging α-synuclein rather than dopaminergic changes. Moreover, dopaminergic imaging has been controversial in monitoring the effects of investigational disease-modifying drugs. For these clinical trials, intense interest in longitudinally imaging α-synuclein as the primary pathologic process has led to efforts toward developing a suitable radiotracer for this key protein. An overview of the present α-synuclein radiotracer development scenario is presented here.
Alpha-synuclein is the defining component of the hallmark pathologic inclusions termed Lewy bodies (LBs), which are characteristic of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), as well as being the major constituent of the glial cytoplasmic inclusions (GCIs) typical of multiple-system atrophy (MSA) . In fact, the presence of intracellular a-synuclein aggregates in multiple neurodegenerative diseases has led to their being cumulatively referred to as synucleinopathies. Various roles of a-synuclein have been implicated in neurodegeneration, such as an involvement in mitochondrial dysfunction, proteasomal dysfunction, and vesicle trafficking within presynaptic dopaminergic neurons (1) . Abnormal a-synuclein function may affect normal dopaminergic release, resulting in decreased synaptic dopaminergic levels that may contribute to Parkinson's symptoms. Several mutations identified in the a-synuclein locus have linked the protein to familial autosomal-dominant PD. However, most PD cases are sporadic (.90%) and thus require another means of early and selective detection in the absence of useful genotyping.
CLINICAL NEED FOR α-SYNUCLEIN TRACER
Despite the efficacy of dopamine-replacement treatments in ameliorating motor symptoms, the progression of PD remains unaltered. Therefore, treatments designed to either slow down disease progression or entirely reverse changes are the new focus of research. Patients with the most to salvage in terms of dopaminergic cell loss will likely be those who gain the most benefit from disease modification strategies. Thus, efforts to use biomarkers to identify those PD patients most eligible for treatment have placed great emphasis on early and accurate diagnosis (2) . Imaging biomarkers using both PET and SPECT have been successfully used to demonstrate clinical algorithms for identifying eligible PD patients at the early stages of motor impairment (3) (4) (5) , before clinically detectable motor symptoms.
Indeed, the concept of clinical premotor PD has been developed to reflect the earliest, nonspecific, and nonmotor manifestations of PD pathology (6) . Braak staging of PD brain suggests that dopaminergic loss occurs at stage III, well after the initial onset of LB appearance; hence, nigrostriatal dopaminergic tract involvement is preceded by LB formation in key areas underlying certain premotor Parkinson's symptoms, for example, loss of olfactory acuity (7) (8) (9) . It has been estimated that years of occult a-synuclein deposition may be occurring before the onset of motor symptoms; hence, the most accurate and earliest definition of premotor PD might better rely on imaging a-synuclein rather than dopaminergic changes (8) .
In addition, although theoretic, it is possible that a-synuclein imaging would serve as the better biomarker of disease status, reflecting the key pathologic insult to the brain, which may change over the course of serial imaging. In fact, studies of PD progression in clinical therapeutic trials using dopaminergic imaging biomarkers have been criticized for the poor correlation with clinical status (10, 11) . Although there are many potential reasons for this, the fact that dopamine cell loss is a downstream effect of a-synuclein deposition is one compelling driver of interest in imaging this protein longitudinally in disease-modifying PD therapeutic trials.
CHARACTERISTICS OF IDEAL α-SYNUCLEIN TRACER
For a tracer to be able to recognize pathologic a-synuclein sensitively and specifically, it must fulfill various criteria ( ½Fig: 1 Fig.  1 ). First, a-synuclein is detected in the pathologic human brain in various forms, including diverse aggregates, fibrillar inclusions, soluble and insoluble oligomers, and pore-like species (12, 13) .
Second, different synucleinopathies are marked by differential locations of a-synuclein aggregates, such that intraneuronal aggregates (e.g., LBs) are typical of PD, whereas oligodendrocytic aggregates (e.g., GCIs) are typical of MSA, both of which should be detected by the optimal tracer, thereby providing the potential for differential diagnosis. Third, although a-synuclein is highly abundant in the nervous system, accounting for 1% of total cytosolic protein (14) , aggregates of a-synuclein have a relatively low density in the diseased brain and additionally have a typically small size, complicating detection. Furthermore, asynuclein is often seen to be colocalized with other aggregating proteins, for example, tau and amyloid-b (Ab) (15), as well as a variety of other proteins accumulated within cellular inclusions, for example, synphilin-1 and parkin. Hence, the said tracer must be able to specifically detect a-synuclein with regard to other codepositing members. Fourth, a-synuclein is known to undergo diverse posttranslational modifications, all of which should be detectable by the tracer. For instance, synucleinopathies are usually associated with inflammation and elevated levels of oxidative stress FIGURE 1. Characteristics of ideal α-synuclein tracer. Tracer should be able to recognize (anticlockwise from left) focal and diffuse aggregates, unstructured and β-pleated sheet fibrillar aggregates, annular/pore-like species, and soluble and insoluble oligomers (A); α-synuclein aggregates (yellow punctata) present in neurons (e.g., in PD) and in glia (e.g., in MSA) (B); α-synuclein aggregates despite their small size and low density in brain and α-synuclein even when it is colocalized with other proteins, for example, tau and Aβ (C); multiple posttranslational modifications undergone by α-synuclein-for example, phosphorylation (P) at serine (16) . Furthermore, phosphorylated a-synuclein immunoreactive for ubiquitin has been detected in both LBs and GCIs (17) , whereas a ubiquitous N-terminal acetylation was detected in LBs from DLB patients (18) .
In addition, there needs to be adequate brain penetration; good washout of nonspecific uptake permitting good signal-to-noise contrast; lack of P-glycoprotein substrate activity; lack of radioactive metabolites; and properties amenable to determining an appropriate quantitative and reproducible outcome measure, preferably a simple, noninvasive tissue-to-blood or tissue-to-reference region ratio. Thus, the optimal a-synuclein tracer must be able to address all of the above factors to provide accurate and comprehensive in vivo detection of pathologic a-synuclein. Although this task appears to be rather daunting, various efforts have been made toward adopting existing amyloid tracers for a-synuclein detection and developing novel molecules of promising potential, as described below.
OVERVIEW OF α-SYNUCLEIN PET TRACERS
This section focuses on some a-synuclein PET tracers in active development-namely, 11 C-Pittsburgh compound-B (PIB), 18 F-BF227, and 125 I-SIL23-demonstrating the principles described in the section above. The PET tracer PIB was originally developed to target Ab plaques, but because it is a derivative of thioflavin T, which stains essentially all types of amyloid, it is conceivable that PIB may also bind to another amyloidogenic protein, that is, a-synuclein. However, the preclinical data on the utility of PIB as an a-synuclein-specific PET tracer appear to be rather inconsistent (19) . Although there is some evidence of PIB binding to aggregated a-synuclein in vitro and in vivo, its much higher affinity for the highly prevalent Ab deposits poses a problem for the selective detection of a-synuclein. Nevertheless, it is theoretically possible that future compounds structurally related to PIB may overcome some of these hurdles.
Another group of Ab-binding compounds that has been investigated for potential affinity to a-synuclein is the benzoxazole family, in particular, BF227. In vitro 18 F-BF227 saturation studies with a-synuclein and Ab 1-42 fibrils indicated that 18 F-BF227 binds with high affinity to 2 binding sites on Ab 1-42 fibrils and to 1 class of binding sites on a-synuclein fibrils ( ½Table 1 Table 1 ) (20) . 18 F-BF227 bound to AD brain homogenates but failed to bind to Ab-free DLB or age-matched control samples. Moreover, BF227 labeled both Ab plaques and LBs in immunohistochemical/ fluorescence analyses of AD and PD brain sections, respectively. 18 F-BF227 has been reported to stain GCIs in postmortem tissues and detect a-synuclein deposits in the living brains of 8 MSA subjects (21) . These data demonstrated that distribution volumes in the subcortical white matter, globus pallidus, substantia nigra, and other regions were higher in MSA subjects than in controls, which was coincident with GCI-rich brain areas in MSA. However, it should be kept in mind that BF227 was initially designed as an Ab imaging agent (22); hence, both its affinity and its selectivity pose questions regarding its applicability in specific a-synuclein detection. A recent study identified 125 I-SIL23 as a novel a-synuclein PET radioligand (23) . The molecule binds to a-synuclein fibrils in postmortem brain tissue from PD patients as well as to a-synuclein in a transgenic mouse model for PD. The density of SIL23 binding sites correlated with the level of fibrillar a-synuclein in PD brain tissue and was high enough to enable in vivo imaging with high-affinity ligands. However, the affinity of SIL23 for a-synuclein may not be optimal for imaging fibrillar a-synuclein in vivo (Table 1) . Furthermore, high nonspecific binding, including nonspecific binding in white matter likely secondary to lipophilic interactions, also appears to limit autoradiography with SIL23 in preliminary experiments.
In conclusion, whereas progress has been made toward the identification of a suitable a-synuclein PET tracer, an ideal candidate still remains elusive.
CHALLENGES AND FUTURE DIRECTIONS
Despite the challenges in developing a successful a-synuclein PET tracer, there are several promising leads under investigation, including both small molecules and antibodies. The latter are particularly interesting insofar as antibodies or antibody fragments directed at pathogenic proteins implicated in neurodegenerative disorders have been suggested as one therapeutic route to modify disease progression. It is possible to label these for PET and SPECT imaging, although the protracted kinetics require longer half-life isotopes.
Recently, an approximately 40-kDa molecule having Specific Molecular Architecture for Recognition and Therapy (SMART) has been generated which detects a-synuclein with high specificity (a-synuclein-SM). One study examining 125 I-a-synuclein-SM in PDlike transgenic (TG) and nontransgenic (NTG) mice demonstrated higher brain uptake and retention in the TG animals than in controls ( ½Fig: 2 Fig. 2) . 125 I-a-synuclein-SM continued to accumulate in the TG brain for at least 9 days. Furthermore, biodistribution analysis of 125 I-a-synuclein-SM showed approximately 15% higher brain penetration relative to blood in the TG mice. Ongoing research will ultimately prove whether this strategy is fruitful toward producing a viable a-synuclein imaging agent.
The importance of this brain target will continue to fuel efforts in this arena, and studies are ongoing to develop additional small molecules targeting a-synuclein as well.
CONCLUSION
a-synuclein is a target of great importance in the pathophysiology of PD and other neurodegenerative disorders, as well as their potential treatment. Up to this point, no viable radiotracer has been generated for the detection of brain a-synuclein. A large scientific effort is currently under way to develop this, with efforts directed toward traditional labeled small molecules as well as antibodies or partial antibodies. It remains to be seen what role the successful a-synuclein radiotracer could serve and whether there are potential advantages from the standpoint of earlier and accurate diagnosis, eligibility assessment for clinical trials, and disease monitoring of therapeutics in both research and clinical contexts.
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